1 / 26

TECHNOLOGY APPRAISAL IN ACTION

TECHNOLOGY APPRAISAL IN ACTION. Mrs Karen Samuels Programme Manager. WHO WHAT WHERE RELATED ORGANISATIONS CHALLENGES FUTURE. WMP MULTIDISCIPLINARY PARTNERSHIP. 1. WMIC 2. WeMeReC 3. WCM Therapeutics and Toxicology Centre 4. YCC Wales (Core WMP). ESTABLISHED 2002.

brant
Download Presentation

TECHNOLOGY APPRAISAL IN ACTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TECHNOLOGY APPRAISAL IN ACTION Mrs Karen Samuels Programme Manager

  2. WHO • WHAT • WHERE • RELATED ORGANISATIONS • CHALLENGES • FUTURE

  3. WMP MULTIDISCIPLINARYPARTNERSHIP • 1. WMIC • 2. WeMeReC • 3. WCM Therapeutics and Toxicology Centre • 4. YCC Wales • (Core WMP)

  4. ESTABLISHED 2002 • Appraised up to 8 High cost drugs per year • Strategic advice • Met 4 times per year

  5. ORGANISATIONAL STRUCTURE

  6. INITIAL PERIOD (2002-2006) • One step process • Public meeting • WMP appraisal team • One medical expert • Patient perspective • Two pharmaceutical company representatives

  7. CHALLENGES • One step • Public nature • Medical expert • PIG submission • Health Economic issues

  8. CHALLENGES (continued) • Small number of specialist medicines • Dependent on pharmaceutical Industry submission • Service links • Need • Commissioners (HCW) • Public demand e.g. trastusumab

  9. APRIL 2007 • Second phase, 32 appraisals per year • 1. High cost • 2. Cancer drugs • 3. Cardiovascular drugs

  10. MODIFIED PROCESS • Met with SMC • New sub group NMG

  11. PROCESS • In the pipeline • MHRA licence (MA) • Company launch in the UK • Preliminary application (Form A) • Detailed application (Form B) • Patient Interest Groups

  12. NMG ROLE AND MEMBERSHIP • Expert clinical & cost effectiveness advice to AWMSG • Broad spectrum membership • Lay representative • ABPI representative • Not in public

  13. DATA CONSIDERED • WMP assessment report (AS AR) • Company response • Company’s detailed application (Form B) • Advice from Medical Expert (s) • Patient interest group submission

  14. AWMSG ROLE AND MEMBERSHIP • Consider strategic, societal, affordability aspects • Broader strategic • Senior NHS managers • Senior Finance directors • Lay representative • ABPI representative

  15. DATA CONSIDERED • NMG preliminary appraisal report (PAR) • Company response to the PAR • Patient Interest Group submissions

  16. HOW? • In public • Announced at the meeting • Minister for Health and Social Services

  17. RELATED ORGANISATIONS • NICE/AWMSG/SMC • ABPI • CDG • All-Wales Cardiac and Cancer networks • Health Commission Wales

  18. REQUEST FOR APPRAISAL OF CANCER DRUGS Is drug/indication licensed? No Yes Is drug being Appraised by NICE? Refer to Cancer New Drugs Group for appraisal No Yes Await NICE guidance Refer to AWMSG for appraisal

  19. ALL WALES CANCERDRUGS GROUP • No backlog • AWCDG to help prioritise • Engaging network • Oncologists • Oncology pharmacists • Horizon scanning

  20. England and Wales - NICE takes precedence • Wales - AWMSG Local MTC’s

  21. SCOTLAND SMC • Streamlined process • Similar paperwork • Simultaneous submissions

  22. ABPI • Users Group • Regular • Input process

  23. FUTURE • Extend to all new medicines? • Increased links with patient groups • Further collaboration with NICE/SMC • Review process after 2 cycles

More Related